Background and Aims: Older patients with metastatic pancreatic adenocarcinoma (MPDAC) are under-represented in clinical trials. Methods: Our single-center, retrospective study enrolled MPDAC patients ≥ 70 treated with chemotherapy Results: 105 patients were divided in groups based on the received treatments: 44 gemcitabine or capecitabine monotherapy (A), 34 nabpaclitaxel-gemcitabine (B) 27 4-drugs combinations (gemcitabine, cisplatin, capecitabine plus either nab-paclitaxel or epirubicin or docetaxel) (C). Group A: median age was 78 (70–87) and Karnofsky performance status (KPS) ≥80 was found in 84% of patients; Group B: median age 77 (71–84) and KPS ≥ 80 in 88% of patients; Group C: median age 73 (70–78) and KPS ≥ 80 in 93% of patients. Median OS was 7.9, 11.7 and 14.2 months in group A, B and C respectively; 1 and 2-year OS were 27% and 8% in group A; 44% and 5% in group B; 52% and 22% in group C. When lung metastatic only patients were excluded, patients <75 and ≥ 75 had similar OS in group A (6.4 vs 5.6 months) and in group B (12.3 vs 11.1 months). In group B grade 3 thrombocytopenia, fatigue and peripheral neuropathy were more frequent in patients ≥ 75. Conclusions: In older patients, combination chemotherapy shows acceptable feasibility and promising efficacy.
Multidrug regimens for treatment of older patients with metastatic pancreatic cancer / Macchini, M.; Chiaravalli, M.; Pircher, C.; Zanon, S.; Peretti, U.; Mazza, ; Valente, M. M.; Fugazza, C.; Gianni, L.; Reni, M.. - In: DIGESTIVE AND LIVER DISEASE. - ISSN 1590-8658. - 53:1(2021), pp. 117-121. [10.1016/j.dld.2020.06.006]
Multidrug regimens for treatment of older patients with metastatic pancreatic cancer
Reni M.
Ultimo
2021-01-01
Abstract
Background and Aims: Older patients with metastatic pancreatic adenocarcinoma (MPDAC) are under-represented in clinical trials. Methods: Our single-center, retrospective study enrolled MPDAC patients ≥ 70 treated with chemotherapy Results: 105 patients were divided in groups based on the received treatments: 44 gemcitabine or capecitabine monotherapy (A), 34 nabpaclitaxel-gemcitabine (B) 27 4-drugs combinations (gemcitabine, cisplatin, capecitabine plus either nab-paclitaxel or epirubicin or docetaxel) (C). Group A: median age was 78 (70–87) and Karnofsky performance status (KPS) ≥80 was found in 84% of patients; Group B: median age 77 (71–84) and KPS ≥ 80 in 88% of patients; Group C: median age 73 (70–78) and KPS ≥ 80 in 93% of patients. Median OS was 7.9, 11.7 and 14.2 months in group A, B and C respectively; 1 and 2-year OS were 27% and 8% in group A; 44% and 5% in group B; 52% and 22% in group C. When lung metastatic only patients were excluded, patients <75 and ≥ 75 had similar OS in group A (6.4 vs 5.6 months) and in group B (12.3 vs 11.1 months). In group B grade 3 thrombocytopenia, fatigue and peripheral neuropathy were more frequent in patients ≥ 75. Conclusions: In older patients, combination chemotherapy shows acceptable feasibility and promising efficacy.File | Dimensione | Formato | |
---|---|---|---|
1-s2.0-S1590865820302693-main.pdf
solo gestori archivio
Tipologia:
PDF editoriale (versione pubblicata dall'editore)
Licenza:
Copyright dell'editore
Dimensione
334.87 kB
Formato
Adobe PDF
|
334.87 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.